The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
 
Hina Khan
Consulting or Advisory Role - Genzyme
Research Funding - Robert A. Winn Diversity in Clinical Trials Award Program
 
Julia Judd
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Asad Ullah
No Relationships to Disclose
 
Girindra Ghanshyam Raval
No Relationships to Disclose
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AADi; AstraZeneca; Bioatla; Mindmed; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - LifeOmic
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Combination therapy for the treatment of TNBC with a PI3K pathway inhibitor that targets PI3KDelta and PI3KGamma (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Matthew James Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
So Yeon Kim
Consulting or Advisory Role - Amgen
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Genentech; MorphoSys (I); Seagen (I); Zentalis
 
Luis E. Raez
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); NantHealth (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Inivata
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Balasz Halmos
No Relationships to Disclose
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; Da Volterra; EMD Serono; Genentech; Genmab; Guardant Health; HUYA Bioscience International; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Nagla Fawzy Abdel Karim
Stock and Other Ownership Interests - Abbott Biotherapeutics (I)
Consulting or Advisory Role - Amgen; Bayer; Bristol Myers Squibb Foundation; G1 Therapeutics; Jazz Pharmaceuticals; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb/Pfizer (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst)